Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib

The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose range 10–200 mg). A kinetic‐pharmacodynamic (K‐PD) model consisting of proliferation, maturation, and blood circulation c...

Descripción completa

Detalles Bibliográficos
Autores principales: Soto, Elena, Banfield, Christopher, Gupta, Pankaj, Peterson, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577017/
https://www.ncbi.nlm.nih.gov/pubmed/32830463
http://dx.doi.org/10.1002/psp4.12548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577017/
https://www.ncbi.nlm.nih.gov/pubmed/32830463
http://dx.doi.org/10.1002/psp4.12548

Ejemplares similares